Seng Gee Lim
Overview
Explore the profile of Seng Gee Lim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
185
Citations
5461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choudhury A, Kulkarni A, Arora V, Soin A, Dokmeci A, Chowdhury A, et al.
Hepatol Int
. 2025 Feb;
19(1):1-69.
PMID: 39961976
Acute-on-chronic liver failure (ACLF) is a condition associated with high mortality in the absence of liver transplantation. There have been various definitions proposed worldwide. The first consensus report of the...
2.
Liu W, Harden S, Tan S, Tan R, Fong S, Tan S, et al.
Mol Ther
. 2024 Sep;
32(11):3895-3914.
PMID: 39318093
In solid tumors, the exhaustion of natural killer (NK) cells and cytotoxic T cells in the immunosuppressive tumor microenvironment poses challenges for effective tumor control. Conventional humanized mouse models of...
3.
Ji F, Tran S, Ogawa E, Huang C, Suzuki T, Wong Y, et al.
J Clin Transl Hepatol
. 2024 Jul;
12(7):646-658.
PMID: 38993510
Background And Aims: As practice patterns and hepatitis C virus (HCV) genotypes (GT) vary geographically, a global real-world study from both East and West covering all GTs can help inform...
4.
Kudaravalli S, Huang D, Yeh M, Trinh L, Tsai P, Hsu Y, et al.
J Hepatol
. 2024 Jun;
81(1):33-41.
PMID: 38906621
Background & Aims: Oral antiviral therapy with nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB) is well-tolerated and lifesaving, but real-world data on utilization are limited. We examined rates of...
5.
Lim S, Teo A, Chan E, Phyo W, Chen D, Hargreaves C
Clin Gastroenterol Hepatol
. 2024 Jun;
22(12):2403-2412.
PMID: 38871150
Background And Aims: Recommendations for stopping nucleoside analogue (NA) therapy in hepatitis B e antigen-negative chronic hepatitis B (CHB) are unclear. End-of-treatment quantitative hepatitis B serum antigen (EOTqHBsAg) thresholds <100...
6.
Quantitative HBeAg is a strong predictor of HBeAg loss among patients receiving pegylated interferon
Huang D, Shen L, Phyo W, Cloherty G, Butler E, Kuhns M, et al.
Antiviral Res
. 2024 Apr;
227:105876.
PMID: 38641023
Background: HBeAg loss is an important endpoint for antiviral therapy in chronic hepatitis B (CHB), however there are no reliable biomarkers to identify patients who will respond to the addition...
7.
Narmada B, Khakpoor A, Shirgaonkar N, Narayanan S, Aw P, Singh M, et al.
J Hepatol
. 2024 Feb;
81(1):42-61.
PMID: 38423478
Background & Aims: Hepatitis B surface antigen (HBsAg) loss or functional cure (FC) is considered the optimal therapeutic outcome for patients with chronic hepatitis B (CHB). However, the immune-pathological biomarkers...
8.
Hou J, Gane E, Balabanska R, Zhang W, Zhang J, Lim T, et al.
Clin Mol Hepatol
. 2024 Jan;
30(2):191-205.
PMID: 38190830
Background/aims: Four-week treatment of linvencorvir (RO7049389) was generally safe and well tolerated, and showed anti-viral activity in chronic hepatitis B (CHB) patients. This study evaluated the efficacy, safety, and pharmacokinetics...
9.
Anderson M, Holzmayer V, Stec M, Cloherty G, Lim S
J Hepatol
. 2023 Nov;
81(1):e24-e25.
PMID: 38036010
No abstract available.
10.